CompanyGraph
What stands out
- Earnings significantly exceed cash generation
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleRevenue is $64,187, lower than 95% of all stocks globally
- PositionOperating margin is -87567.6%, lower than 95% of its Biotechnology peers (median -38%)
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
What stands out
- Earnings significantly exceed cash generation
Financials view
Market Capitalization
3.48BHKD443.10M · vs all stocks (USD)
Revenue (TTM)
503.55KHKD64.19K · vs all stocks (USD)
Beta
2.57xvs all stocks
52-Week Change
-10.00%vs all stocks
Market Capitalization
3.48BHKD443.10M · vs all stocks (USD)
Enterprise Value
3.02BHKD385.01M · vs all stocks (USD)
Forward P/E
1.87xvs Biotechnology peers
Enterprise to Revenue
6.00Kxvs Biotechnology peers
Enterprise to EBITDA
-9.16xvs Biotechnology peers
Return on Assets (TTM)
-44.48%vs Biotechnology peers
Revenue (TTM)
503.55KHKD64.19K · vs all stocks (USD)
Revenue per Share (TTM)
0.0028HKDUpdated Sep 20, 2026Quarterly Revenue Growth
-94.50%vs Biotechnology peers
Gross Profit (TTM)
-6.48MHKD-825.92K · vs all stocks (USD)
EBITDA (TTM)
-329.84MHKD-42.04M · vs all stocks (USD)
Net Income (TTM)
996.74MHKD127.05M · vs all stocks (USD)
Operating Cash Flow (TTM)
-194.83MHKD-24.83M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
-205.09MHKD-26.14M · vs all stocks (USD)
Trailing Annual Dividend Rate
0.00HKDUpdated Sep 20, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Biotechnology peers
Revenue
3.50MCNYFY2025 · Dec 31, 2025Cost of Goods Sold
765.00KCNYFY2025 · Dec 31, 2025Gross Profit
2.74MCNYFY2025 · Dec 31, 2025Operating Income
-217.07MCNY-32.39M · vs all stocks (USD)
Pre-tax Income
-205.09MCNYFY2025 · Dec 31, 2025Income Tax Expense
0.00CNYFY2025 · Dec 31, 2025Net Income
-205.09MCNYFY2025 · Dec 31, 2025EBIT
-204.72MCNYFY2025 · Dec 31, 2025EBITDA (Income Statement)
-174.32MCNYFY2025 · Dec 31, 2025Research & Development
182.34MCNYFY2025 · Dec 31, 2025Selling, General & Administrative
33.97MCNYFY2025 · Dec 31, 2025Non-operating Interest Income
6.33MCNYFY2025 · Dec 31, 2025Non-operating Interest Expense
377.00KCNYFY2025 · Dec 31, 2025EPS (Basic)
-0.1600CNYFY2025 · Dec 31, 2025EPS (Diluted)
-0.1600CNYFY2025 · Dec 31, 2025Basic Shares Outstanding
1.26BSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
1.26BSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
-205.09MCNYFY2025 · Dec 31, 2025Preferred Stock Dividends
0.00CNYFY2025 · Dec 31, 2025Operating Cash Flow
-175.63MCNYFY2025 · Dec 31, 2025Free Cash Flow
-175.64MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
267.63MCNYFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-205.09MCNYFY2025 · Dec 31, 2025Stock-based Compensation
6.69MCNYFY2025 · Dec 31, 2025Other Non-cash Items
-5.95MCNYFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
40.99MCNYFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-12.27MCNYFY2025 · Dec 31, 2025Capital Expenditures
-12.00KCNYFY2025 · Dec 31, 2025Net Intangibles (CF)
0.00CNYFY2025 · Dec 31, 2025Sale of Investments
0.00CNYFY2025 · Dec 31, 2025Net Investing Cash Flow
-12.00KCNYFY2025 · Dec 31, 2025Long-term Debt Payments
-93.99MCNYFY2025 · Dec 31, 2025Net Short-term Debt Issuance
-73.99MCNYFY2025 · Dec 31, 2025Other Financing Charges
143.77MCNYFY2025 · Dec 31, 2025Net Financing Cash Flow
-23.72MCNYFY2025 · Dec 31, 2025Shares Outstanding
1.30BSharesUpdated Sep 20, 2026Float Shares
776.85MSharesUpdated Sep 20, 2026% Held by Insiders
34.14%vs all stocks
% Held by Institutions
15.04%vs all stocks
Total Cash (MRQ)
118.92MHKD15.16M · vs all stocks (USD)
Total Cash per Share (MRQ)
0.0800HKDUpdated Sep 20, 2026Total Debt (MRQ)
2.44MHKD311.08K · vs all stocks (USD)
Current Ratio (MRQ)
0.7310xvs Biotechnology peers
Book Value per Share (MRQ)
-0.7404HKDUpdated Sep 20, 2026Total Assets
457.92MCNY68.33M · vs all stocks (USD)
Total Current Assets
335.83MCNYFY2025 · Dec 31, 2025Total Liabilities
2.26BCNYFY2025 · Dec 31, 2025Total Non-current Assets
122.09MCNYFY2025 · Dec 31, 2025Total Non-current Liabilities
504.60MCNYFY2025 · Dec 31, 2025Total Current Liabilities
1.75BCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents
267.63MCNYFY2025 · Dec 31, 2025Other Short-term Investments
18.39MCNYFY2025 · Dec 31, 2025Accounts Receivable
3.00KCNYFY2025 · Dec 31, 2025Inventory
9.86MCNYFY2025 · Dec 31, 2025Accounts Payable
107.99MCNYFY2025 · Dec 31, 2025Short-term Debt
10.61MCNYFY2025 · Dec 31, 2025Long-term Debt
0.00CNYFY2025 · Dec 31, 2025Common Stock (Book)
839.00KCNYFY2025 · Dec 31, 2025Retained Earnings
-10.75BCNYFY2025 · Dec 31, 2025Total Shareholders' Equity
-1.80BCNY-268.20M · vs all stocks (USD)
Treasury Stock
23.00KCNYFY2025 · Dec 31, 202552-Week Low
1.32HKDUpdated Sep 20, 202652-Week High
3.20HKDUpdated Sep 20, 202652-Week Change
-10.00%vs all stocks
Beta
2.57xvs all stocks
50-Day MA
2.01HKDUpdated Sep 20, 2026200-Day MA
2.27HKDUpdated Sep 20, 2026Avg 10-Day Volume
4.70MSharesUpdated Sep 20, 2026Avg 30-Day Volume
4.22MSharesUpdated Sep 20, 2026Diluted EPS (TTM)
-0.2000HKDUpdated Sep 20, 2026Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Operating margin is -87567.6%, lower than 95% of its Biotechnology peers (median -38%)Significant
Operating margin: -875.676Industry median: -0.38Industry P5: -43.63Peers compared: 260
Profit margin is 197942.8%, higher than 95% of its Biotechnology peers (median -47.7%)Significant
Profit margin: 1,979.428Industry median: -0.48Industry P95: 0.42Peers compared: 260
Current ratio is 0.73×, lower than 95% of its Biotechnology peers (median 5.71×)Significant
Current ratio: 0.73Industry median: 5.71Industry P5: 1.02Peers compared: 260
Structural Tensions
Earnings significantly exceed cash generationSignificant
Net Income (USD, TTM): 127,053,856.467Operating Cash Flow (USD, TTM): -24,834,470.22
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Revenue is $64,187, lower than 95% of all stocks globallySignificant
Revenue (USD): 64,187.136Global P5: 33,357,653.812
Companies that share the same coordination system — how they create, deliver, or capture value.
Guanhao Biotech Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Zhejiang Shouxiangu Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Anhui Sunhere Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Baotou Dongbao Bio-Tech Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Guizhou Yibai Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
ClearPoint Neuro Inc.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Hangzhou Tianmu-Shan Pharmaceutical Enterprise Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Nanjing Medlander Medical Inc.
Tier 1ProductionApproval-Gated PipelineRule
Jw Pharmaceutical Corporation
Tier 1ProductionApproval-Gated PipelineRuleFlow
Shanghai Kehua Bio-Engineering Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule